Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents

Treatment resistance, whether inherent or acquired, is a major problem reducing the activity of conventional and newer, molecularly targeted, cancer drugs. A more complex picture of the causes and contributions of specific forms of resistance is now emerging through application of pharmacological, proteomic and gene expression technologies and we have entered an exciting time where new molecular research tools are being applied not only to characterise the causes of such resistance, but to identify rational new treatments and treatment combinations that are being rapidly translated to clinical evaluations with increasing success. This review outlines many of the contributing causes of resistance to established cytotoxics and to the new breed of molecularly targeted agents, both monoclonal antibodies and small molecules, and the research methods being used to wage war on resistant cancer.

[1]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[2]  A. Scott,et al.  Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity , 2005, Clinical Cancer Research.

[3]  G. Hortobagyi,et al.  The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins , 2004, British Journal of Cancer.

[4]  A. Protopopov,et al.  The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis , 2007, Cancer cell.

[5]  Roman Rouzier,et al.  Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma , 2005, Cancer.

[6]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[7]  M. Piccart,et al.  Progress and new standards of care in the management of HER-2 positive breast cancer. , 2007, European journal of cancer.

[8]  G. Tusnády,et al.  Membrane topology of human ABC proteins , 2006, FEBS letters.

[9]  N. Munshi,et al.  The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. , 2006, European journal of cancer.

[10]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[11]  R. Nahta,et al.  Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.

[12]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[13]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[14]  S. Abdulkadir,et al.  A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance , 2004, Oncogene.

[15]  E. Moran,et al.  The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. , 1997, Biochemical pharmacology.

[16]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[17]  Maria Kavallaris,et al.  Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia – An in vivo study , 2006, Proteomics.

[18]  R. Nicholson,et al.  Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. , 2004, Endocrine-related cancer.

[19]  R. Callaghan,et al.  The translocation mechanism of P‐glycoprotein , 2006, FEBS letters.

[20]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[21]  J. Zalcberg,et al.  Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs , 2005, Oncogene.

[22]  F. Cappuzzo,et al.  Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Clarke,et al.  ATP binding cassette transporters and drug resistance in breast cancer. , 2003, Endocrine-related cancer.

[24]  R. Kerbel,et al.  Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. , 2004, International journal of radiation oncology, biology, physics.

[25]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[27]  C. Sotiriou,et al.  Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer , 2002, Breast Cancer Research.

[28]  S. Bates,et al.  ABC transporters and inhibitors: new targets, new agents. , 2002, Current opinion in investigational drugs.

[29]  T Tanaka,et al.  Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. , 2001, Cancer research.

[30]  M. Bittner,et al.  Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. , 2000, Cancer research.

[31]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Fojo,et al.  The role of ABC transporters in clinical practice. , 2003, The oncologist.

[33]  C. la Vecchia,et al.  Diverging trends in breast cancer mortality within Switzerland. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[35]  Asad U. Khan,et al.  Ribozyme: a clinical tool. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[36]  Paolo Valerio,et al.  Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. , 2006, Current medicinal chemistry.

[37]  R. Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .

[38]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[39]  W. Gradishar,et al.  Gene expression in breast cancer , 2006, Current treatment options in oncology.

[40]  B. Sarkadi,et al.  ABCG2 – a transporter for all seasons , 2004, FEBS letters.

[41]  G. Qiao,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .

[42]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[43]  B. Trock,et al.  Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. , 2005, Seminars in oncology.

[44]  M. Pirmohamed,et al.  hOCT 1 and resistance to imatinib. , 2005, Blood.

[45]  P. Borst,et al.  Multidrug resistance-associated proteins 3, 4, and 5 , 2007, Pflügers Archiv - European Journal of Physiology.

[46]  B. Druker,et al.  STI571 as a Targeted Therapy for CML , 2003, Cancer investigation.

[47]  F. de Longueville,et al.  Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes , 2004, Cancer Research.

[48]  Edward S. Kim,et al.  Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib , 2007, Clinical Cancer Research.

[49]  A. Isaksson,et al.  Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles , 2005, British Journal of Cancer.

[50]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[51]  Mariël Brok,et al.  Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.

[52]  W. Berger,et al.  Cellular functions of vaults and their involvement in multidrug resistance. , 2006, Current drug targets.

[53]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[54]  M. Pollak,et al.  Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells , 2004, International journal of cancer.

[55]  Y. S. Kim,et al.  Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. , 2004, Cancer letters.

[56]  P. Houghton,et al.  Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. , 2006, Cancer research.

[57]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[58]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Clynes,et al.  RNA Interference with siRNA. , 2006, Cancer genomics & proteomics.

[60]  M. Gottesman,et al.  Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[61]  B. Sarkadi,et al.  Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[62]  D. Keppler,et al.  Detection of the Human Organic Anion Transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in Liver and Hepatocellular Carcinoma , 2003, Laboratory Investigation.

[63]  Yaming Su,et al.  Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. , 2004, Molecular pharmaceutics.

[64]  R. O'connor,et al.  The pharmacology of cancer resistance. , 2007, Anticancer research.

[65]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[67]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[68]  Naoto T Ueno,et al.  P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. , 2004, Cancer research.

[69]  A. Vlahou,et al.  Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. , 2005, Oncology reports.

[70]  Naoto T. Ueno,et al.  P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.

[71]  I. Fichtner,et al.  Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance , 2006, Proteomics.

[72]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[73]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[74]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[75]  H. Tsuda,et al.  Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. , 2006, Oncology reports.

[76]  J. Stec,et al.  Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer , 2002, Cancer journal.

[77]  R. Pérez-Tomás,et al.  Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. , 2006, Current medicinal chemistry.

[78]  I. Ghobrial,et al.  New Frontiers in the Treatment of Multiple Myeloma , 2006, TheScientificWorldJournal.

[79]  U. Zangemeister‐Wittke,et al.  Antisense molecules for targeted cancer therapy. , 2006, Critical reviews in oncology/hematology.

[80]  J. Reis-Filho,et al.  The impact of expression profiling on prognostic and predictive testing in breast cancer , 2006, Journal of Clinical Pathology.

[81]  A. Sparreboom,et al.  Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel , 2005, Cancer biology & therapy.

[82]  D. Chauhan,et al.  A novel proteasome inhibitor NPI-0052 as an anticancer therapy , 2006, British Journal of Cancer.

[83]  Munir Pirmohamed,et al.  Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.

[84]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  T. Fojo,et al.  Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. , 2004, Current drug targets.

[86]  L. O’Driscoll,et al.  A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer , 2006, Cancer Chemotherapy and Pharmacology.

[87]  R. Kim,et al.  Organic anion‐transporting polypeptide (OATP) transporter family and drug disposition , 2003, European journal of clinical investigation.

[88]  Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. , 2005 .

[89]  J. Fletcher,et al.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Chava Kimchi-Sarfaty,et al.  P-glycoprotein: from genomics to mechanism , 2003, Oncogene.

[91]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[92]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[93]  C. Perou,et al.  Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.

[94]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[95]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[96]  Y. Hathout,et al.  Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. , 2004, Journal of proteome research.

[97]  Biaoyang Lin,et al.  Proteins Associated with Cisplatin Resistance in Ovarian Cancer Cells Identified by Quantitative Proteomic Technology and Integrated with mRNA Expression Levels*S , 2006, Molecular & Cellular Proteomics.

[98]  N. Seki,et al.  Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. , 2005, Oncology Report.

[99]  R. Gust,et al.  Dinuclear Alkylamine Platinum(II) Complexes of [1,2‐Bis(4‐fluorophenyl)ethylenediamine]platinum(II): Influence of Endocytosis and Copper and Organic Cation Transport Systems on Cellular Uptake , 2006, ChemMedChem.

[100]  L. O’Driscoll,et al.  Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance , 1997, International journal of cancer.

[101]  Zhe-Sheng Chen,et al.  ABCC10, ABCC11, and ABCC12 , 2007, Pflügers Archiv - European Journal of Physiology.

[102]  D. Steinemann,et al.  BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. , 2005, Cancer genetics and cytogenetics.

[103]  Kenneth C Anderson,et al.  Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. , 2007, Experimental hematology.

[104]  J. Harbott,et al.  Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance , 2006, Leukemia.

[105]  Gema Moreno-Bueno,et al.  Transcriptional profiling of MCF7 breast cancer cells in response to 5‐Fluorouracil: Relationship with cell cycle changes and apoptosis, and identification of novel targets of p53 , 2006, International journal of cancer.

[106]  S. Cole,et al.  Transport of glutathione and glutathione conjugates by MRP1. , 2006, Trends in pharmacological sciences.